ESPR · Esperion Therapeutics, Inc. · Stock research

Current Thesis

The special situation is finished. ARCHIMED announced the close of its acquisition of Esperion on 2026-07-13, and per the buyer's own release "Esperion common stock has ceased trading and is no longer listed on the NASDAQ Stock Market." Holders of record received $3.16 per share in cash — a 58% premium to the 2026-04-30 close — plus the right to contingent milestone payments of up to $100M in aggregate, which lifts headline equity value to roughly $1.1B (€962M) fully diluted only if the commercial milestones are fully achieved. The last completed daily bar the pipeline holds is $3.18 on 2026-07-10, two cents above the cash number, and there are no bars after it. The narrative leg an investor was buying — deal certainty compressing an arb spread — was paid out in cash; there is no longer a listed instrument through which to express any view on bempedoic acid. Life-cycle label: DEAD, dated to the 2026-07-13 close and delisting. Dead here means terminated by completion, and the structure the tape traded on no longer exists.

Bullish and bearish views on Esperion Therapeutics, Inc.

The model's bull view on Esperion Therapeutics, Inc. (ESPR), in brief: Every gate cleared on schedule: HSR waiting period expired 11:59pm ET on 2026-06-15, German antitrust cleared before the vote, and holders adopted the agreement on 2026-07-08 by 135,326,793 for versus 22,750,628 against with 496,194 abstaining. The bear view: There is nothing to own. The common stock was cancelled into cash on 2026-07-13; any quote screen still showing an ESPR last price is carrying stale data from on or before 2026-07-10. The milestone tail is a low-probability payout on the disclosed math: Q1 2026 US product… Both cases follow in full.

Bull Case

• Every gate cleared on schedule: HSR waiting period expired 11:59pm ET on 2026-06-15, German antitrust cleared before the vote, and holders adopted the agreement on 2026-07-08 by 135,326,793 for versus 22,750,628 against with 496,194 abstaining.
• Financing did not wobble: unitranche debt was provided by Pharmakon Advisors and the acquisition was executed through ARCHIMED's MED Platform II fund, per the 2026-07-13 completion release.
• The cash leg paid at $3.16, versus a pre-announcement reference of the 2026-04-30 close that the buyer describes as a 58% discount to the deal price.
• The residual tail is real but private: up to $100M in milestone payments, structured as $40M if bempedoic-acid (NEXLETOL/NEXLIZET) US net sales exceed $350M in 2027 and $60M if ENBUMYST/bumetanide US net sales reach $160M in any single year through 2030, per the merger terms announced 2026-05-01.
• The underlying business was growing into the bid: Q1 2026 revenue $80.1M, +23% YoY, split $43.4M product and $36.7M collaboration, with net loss narrowing to $25.2M from $40.5M a year earlier.

Bear Case

• There is nothing to own. The common stock was cancelled into cash on 2026-07-13; any quote screen still showing an ESPR last price is carrying stale data from on or before 2026-07-10.
• The milestone tail is a low-probability payout on the disclosed math: Q1 2026 US product revenue was $43.4M against a $350M calendar-2027 threshold for the $40M tranche.
• The CVR does not trade and is not listed, so the tail cannot be bought, sold or marked by a public price.
• Esperion is now a private portfolio company of ARCHIMED, so the Q2 2026 print that would normally have landed in early August never becomes a public datapoint, and future net-sales disclosure is a contractual matter between the buyer and CVR holders rather than an SEC filing an outside reader can pull.
• The 52-week high of $4.08 predates the 2026-05-01 announcement and was never reachable under fixed terms; the RSI(14) of 61.5 on the final bar is an artifact of a pinned arb tape, not momentum.

Setup & Price Structure

• One gap did the whole job: the 2026-05-01 announcement lifted the stock from roughly $2 into the low-$3s, after which the tape sat on the cash terms for ten weeks.
• Final observable pricing: last completed daily close $3.18 on 2026-07-10, 3-month return +46.5%, 22.1% below the $4.08 52-week high. The close printed two cents above the $3.16 cash consideration while the CVR cap was $100M in aggregate across the roughly 257.7M shares in the record-date count used for the vote — the marginal buyer was paying a token amount for the milestone tail. That is measured; the inference is that the market assigned the CVR close to nothing.
• Crowding and positioning read differently for a closed arb than for a momentum name. The observables: no earnings date ahead (the issuer no longer reports), no insider-transaction flow to monitor (Section 16 obligations end with deregistration), no rising moving average to sit above (the series stops at 2026-07-10), and a stockholder tally in which 22,750,628 shares were voted against — dissent that is disclosed, and separate from any appraisal demands, which are not publicly tallied.
• No base, no breakout shelf, no continuation structure. The price series terminates.

Catalyst Calendar (next 30 days)

• 2026-08-08 through 2026-09-07: no scheduled catalyst for the security. No earnings date, no PDUFA, no scheduled regulatory or corporate event affecting a listed ESPR share, because none exists after 2026-07-13.
• 2027-12-31 (measurement-period end, est. determination in 2028): close of the calendar-2027 window for the $40M bempedoic-acid milestone (US net sales above $350M).
• 2030-12-31: final year of the window for the $60M ENBUMYST/bumetanide milestone (US net sales at or above $160M in any single year).

What Would Change Our Mind

The only thing that reopens this file is a tape. Esperion's shares ceased trading and delisted on 2026-07-13 on completion of the ARCHIMED merger, so a daily close below $3.16 cannot print — the level that would once have flagged deal-break risk is unobservable, and the $3.18 close on 2026-07-10 stands as the last. Three developments would force a rewrite: a Nasdaq or NYSE listing notice restoring an Esperion equity security (a re-IPO of the asset under ARCHIMED ownership, or a reissued symbol); a public disclosure that the 2026-07-13 completion was rescinded or a closing condition failed after the fact; or a milestone determination made public showing bempedoic-acid US net sales tracking materially above the $43.4M quarterly level reported for Q1 2026, which would change the read on the CVR tail. Absent one of those, this is a closed cash outcome and the correct handling is to stop tracking a price on it.

Correlation Notes

• Any residual index or ETF linkage ended mechanically with the cancellation of the shares on 2026-07-13; there is no constituent left to weight.
• The deal is a live comparable for the 2026 small/mid-cap biotech take-private set: a sponsor bid a 58% premium to the 2026-04-30 close on a commercial-stage cardiovascular asset and used a $100M CVR to bridge the valuation gap, with unitranche debt from Pharmakon Advisors rather than a syndicated loan. Comparable structures are what to look for in other commercial-stage names carrying a growing revenue line and a persistent loss.
• ARCHIMED's MED Platform II remains an active healthcare acquirer following the 2026-07-13 close; further take-privates from that fund would be read against this template.
• Oral non-statin LDL-lowering loses a public revenue comparable: the last public print for bempedoic acid was $43.4M of product revenue in Q1 2026, and no further quarterly series will be published while the asset sits inside a private owner.